Nantes, June 14, 2023 – 8 p.m. CEST – Pherecydes Pharma (FR0011651694 – ALPHE), a biotechnology company specializing in precision phage therapy intended to treat resistant and/or complicated bacterial infections, announces today that the Commercial Court of Lyon rejected Akkadian’s request to postpone the vote on the merger with Erytech Pharma (Erytech).
Pherecydes Pharma, which voluntarily intervened in the legal proceedings initiated by Akkadian (Pherecydes Pharma press release of June 5, 2023), welcomes the interim order issued today by the President of the Commercial Court of Lyon . The latter rejected the attempt by Akkadian Partners to obtain the postponement of the vote on the merger. Consequently, the shareholders of the two companies will be able to validly vote on the merger on June 23, 2023.
An expert has been appointed to examine the merger parity and will have to submit his report to the parties within 4 months. This expertise will be carried out at the expense of Akkadian Partners, which has also been ordered to compensate Pherecydes Pharma (as well as Erytech) for the costs that the company has incurred in the context of the procedure.
To receive all of Pherecydes Pharma’s financial information in real time, send a request by email to [email protected]. Your registration will be immediate.